Associate Professor Jennifer Byrne

Associate Professor
Paediatrics & Child Health, Children's Hospital, Westmead

C29 - Children's Hospital Westmead
The University of Sydney
NSW 2006 Australia

T: +61 2 9845 3027
F: +61 2 9845 3078
E:
W: Related website

Biographical details

Career Chronology [More...]

Research interests

Jennifer Byrne is a molecular biologist based at the Children’s hospital at Westmead in the Oncology Research Unit. She studies the functions of amplification target genes which are overexpressed in multiple cancers, and the clinical significance of target gene overexpression.

Keywords

Inflammation; Biochemistry; Cancer

Publications

2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

2014

   
  • Roslan, N., Bieche, I., Bright, R., Lidereau, R., Chen, Y., Byrne, J. (2014), TPD52 Represents a Survival Factor in ERBB2-Amplified Breast Cancer Cells. Molecular Carcinogenesis. 53(10), 807-819. [Abstract]
  • Byrne, J., Frost, S., Chen, Y., Bright, R. (2014), Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?. Tumour Biology. 35(8), 7369-7382. [Abstract]
  • Shahheydari, H., Frost, S., Smith, B., Groblewski, G., Chen, Y., Byrne, J. (2014), Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Molecular Biology Reports. 41, 4565¿4572. [Abstract]
  • Biesemann, C., Gronborg, M., Luquet, E., Wichert, S., Bernard, V., Bungers, S., Cooper, B., Varoqueaux, F., Li, L., Byrne, J., Urlaub, H., Jahn, O., Brose, N., Herzog, E. (2014), Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting. The EMBO journal. 33(2), 157-70. [Abstract]
  • Saletta, F., Wadham, C., Ziegler, D., Marshall, G., Haber, M., Mccowage, G., Norris, M., Byrne, J. (2014), Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clinical. 1, 59-77.
  • Kamili, A., Byrne, J. (2014), Lipidomics in breast cancer. In: Omics Approaches in Breast Cancer: Towards Next-Generation Diagnosis, Prognosis and Therapy. (pp.225-244).India: Springer India.

2013

   
  • Messenger, S., Thomas, D., Falkowski, M., Byrne, J., Gorelick, F., Groblewski, G. (2013), Tumor protein D52 controls trafficking of an apical endolysosomal secretory pathway in pancreatic acinar cells. American Journal of Physiology. Gastrointestinal and Liver Physiology. 305(6), G439-G452. [Abstract]
  • Chen, Y., Kamili, A., Hardy, J., Groblewski, G., Khanna, K., Byrne, J. (2013), Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle. 12(18), 3083-3097. [Abstract]
  • Bright, J., Schultz, H., Byrne, J., Bright, R. (2013), Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. Oncoimmunology. 2(7), e25049. [Abstract]

2012

   
  • Byrne, J., Chen, Y., Martin La Rotta, N., Peters, G. (2012), Challenges in Identifying Candidate Amplification Targets in Human Cancers: Chromosome 8q21 as a Case Study. Genes & Cancer. 3(2), 87-101. [Abstract]
  • Della-Franca, A., Chen, Y., Byrne, J. (2012), TPD52 (Tumor Protein D52). In: Encyclopaedia of Signalling Molecules. (pp.1906-1911).United States: Springer.

2011

   
  • Della-Franca, A., Byrne, J. (2011), TPD52(tumor protein D52). Atlas of Genetics and Cytogenetics in Oncology and Haematology. 15(6), 486-492.
  • Machado, I., López-Guerrero, J., Calabuig-Fariñas, S., Hardy, J., Scotlandi, K., Picci, P., Byrne, J., Llombart-Bosch, A. (2011), Clinical significance of tumor protein D52 immunostaining in a large series of Ewing's sarcoma family of tumors. Pediatric and Developmental Pathology. , 255-256. [Abstract]

2010

   
  • Andrés-Delgado, L., Antón, O., Madrid, R., Byrne, J., Alonso, M. (2010), Formin INF2 regulates MAL-mediated transport of Lck to the plasma membrane of human T lymphocytes. Blood. 116(26), 5919-5929. [Abstract]
  • Madrid, R., Aranda, J., Rodríguez-Fraticelli, A., Ventimiglia, L., Andrés-Delgado, L., Shehata, M., Fanayan, S., Shahheydari, H., Gómez, S., Jiménez, A., Martín-Belmonte, F., Byrne, J., Alonso, M. (2010), The formin INF2 regulates basolateral-to-apical transcytosis and lumen formation in association with Cdc42 and MAL2. Developmental Cell. 18(5), 814-827. [Abstract]
  • Edo De Bock, C., Lin, Z., Mekkawy, A., Byrne, J., Wang, Y. (2010), Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. International Journal of Oncology. 36(5), 1155-1163. [Abstract]
  • Thomas, D., Martin, C., Weng, N., Byrne, J., Groblewski, G. (2010), Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. American Journal of Physiology: Cell Physiology. 298(3), C725-C739. [Abstract]
  • Byrne, J., Maleki, S., Hardy, J., Gloss, B., Murali, R., Scurry, J., Fanayan, S., Emmanuel, C., Hacker, N., Sutherland, R., Defazio, A., O'Brien, P. (2010), MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 10, 497. [Abstract]

2009

   
  • Lewis, J., Sullivan, L., Byrne, J., de Riese, W., Bright, R. (2009), Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunology, Immunotherapy. 58(8), 1337-1349. [Abstract]
  • Alagaratnam, S., Hardy, J., Lothe, R., Skotheim, R., Byrne, J. (2009), TPD52, a candidate gene from genomic studies, is overexpressed in testicular germ cell tumours. Molecular and cellular endocrinology. 306(0), 75-80. [Abstract]
  • Fanayan, S., Shehata, M., Agterof, A., McGuckin, M., Alonso, M., Byrne, J. (2009), Mucin 1 (MUC1) is a novel partner for MAL2 in breast carcinoma cells. BMC Cell Biology. 10(0), 7. [Abstract]
  • Weidenhofer, J., Byrne, J. (2009), Isolation of Nucleic Acids from Hard Tissues. In: Handbook of Nucleic Acid Purification. (pp.427-448).United States: CRC Press.

2008

   
  • Shehata, M., Bièche, I., Boutros, R., Weidenhofer, J., Fanayan, S., Spalding, L., Zeps, N., Byth, K., Bright, R., Lidereau, R., Byrne, J. (2008), Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52. Clinical Cancer Research. 14(16), 5050-5060. [Abstract]
  • Payton, L., Lewis, J., Byrne, J., Bright, R. (2008), Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunology, Immunotherapy. 57(6), 799-811. [Abstract]
  • Shehata, M., Weidenhofer, J., Thamotharampillai, K., Hardy, J., Byrne, J. (2008), Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Critical Reviews in Oncogenesis. 14(1), 33-55. [Abstract]